Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.

Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 05/2008; 52(8):2750-4. DOI:10.1128/AAC.00044-08
Source: PubMed

ABSTRACT Although antimicrobial therapy of leptospirosis has been studied in a few randomized controlled clinical studies, those studies were limited to specific regions of the world and few have characterized infecting strains. A broth microdilution technique for the assessment of antibiotic susceptibility has been developed at Brooke Army Medical Center. In the present study, we assessed the susceptibilities of 13 Leptospira isolates (including recent clinical isolates) from Egypt, Thailand, Nicaragua, and Hawaii to 13 antimicrobial agents. Ampicillin, cefepime, azithromycin, and clarithromycin were found to have MICs below the lower limit of detection (0.016 microg/ml). Cefotaxime, ceftriaxone, imipenem-cilastatin, penicillin G, moxifloxacin, ciprofloxacin, and levofloxacin had MIC(90)s between 0.030 and 0.125 microg/ml. Doxycycline and tetracycline had the highest MIC(90)s: 2 and 4 microg/ml, respectively. Doxycycline and tetracycline were noted to have slightly higher MICs against isolates from Egypt than against strains from Thailand or Hawaii; otherwise, the susceptibility patterns were similar. There appears to be possible variability in susceptibility to some antimicrobial agents among strains, suggesting that more extensive testing to look for geographic variability should be pursued.

0 0
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Third generation cephalosporins are commonly used in the treatment of leptospirosis. The efficacy of first generation cephalosporins has been less well-studied. Susceptibility testing of 13 Leptospira strains (11 serovars) to cefazolin and cephalexin was conducted using broth microdilution. Median minimal inhibitory concentration (MIC) for cefazolin and cephalexin ranged from < 0.016 to 2 μg/mL (MIC(90) = 0.5 μg/mL) and from 1 to 8 μg/mL (MIC(90) = 8 μg/mL), respectively. Efficacy of cefazolin and cephalexin in an acute lethal hamster model of leptospirosis was studied. Survival rates for cefazolin were 80%, 100%, and 100%, and survival rates for cephalexin were 50%, 80%, and 100% (treated with 5, 25, and 50 mg/kg per day for 5 days, respectively). Each treatment group showed improved survival compared with no treatment (P < 0.01), and none of the therapies, regardless of dose, was statistically significantly different than doxycycline. These results support a potential role for first generation cephalosporins as alternative therapies for leptospirosis.
    The American journal of tropical medicine and hygiene 11/2011; 85(5):905-8. · 2.53 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Pathogenic Leptospira spp., the causative agents of leptospirosis, are slow growing Gram-negative spirochetes. Isolation of Leptospira from clinical samples and testing of antimicrobial susceptibility is difficult and time-consuming. Here, we described the development of a new solid medium that facilitates more rapid growth of Leptospira spp., and use of this to evaluate the Etest to determine antimicrobial minimum inhibitory concentrations (MIC) to drugs in common use for leptospirosis. The medium was developed by evaluating the effect of numerous factors on the growth rate of L. interrogans strain NR-20157. These included the type of base agar, concentration of rabbit serum (RS), and concentration and duration of CO(2) incubation during the initial period of culture. The fastest growth rate of NR-20157 was achieved using Noble agar base supplemented with 10% RS (named LVW agar), with an initial incubation at 30°C in 5% CO(2) for 2 days prior to continuous culture in air at 30°C. These conditions were used to develop the Etest for three species (L. interrogans (NR-20161), L. kirschnerii (NR-20327) and L. borgpetersenii (NR-20151)). The MICs were read on day 7 for all samples. Etest was then performed on 109 isolates of pathogenic Leptospira spp. The MIC(90) for penicillin G, doxycycline, cefotaxime, ceftriaxone and chloramphenicol were 0.64 units/mL, 0.19, 0.047, 0.5 and 2 μg/mL, respectively. The use of LVW agar, which enables rapid growth, isolation of single colonies and simple antimicrobial susceptibility testing for Leptospira spp., provides an opportunity for new areas of fundamental and applied research.
    Antimicrobial Agents and Chemotherapy 10/2012; · 4.57 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Some antimicrobial agents are active in vitro against Leptospiras. The use of penicillins at the late stage of leptospirosis is still controversial. We aimed to evaluate the use of penicillin in patients with leptospirosis-associated acute kidney injury (AKI). A retrospective study was conducted of patients with leptospirosis admitted to two hospitals in Fortaleza city, Brazil, between 1985 and 2008. AKI was defined according to the RIFLE and AKIN classifications. Patients were divided in two groups according to whether they were treated with a penicillin or not. Two hundred and eighty-seven patients were included, with an average age of 36·8±15·6 years and mostly male (80·8%). One hundred and twelve patients (39%) received a penicillin. Patients treated with a penicillin were younger (32±14 years vs. 39±16 years, P=0·0002) and had a shorter hospital stay (8·4±5·0 vs. 11±7·7 days, P<0·0001). There was no difference in the onset of symptoms before hospital admission between the two groups (6·5±3·0 vs. 7·7±4·7, P=0·33). Systolic blood pressure was lower in the penicillin group (111±21 vs. 119±22 mmHg, P=0·04). AKI, need of dialysis and renal recovery at the time of hospital discharge were more frequent in patients who did not use a penicillin (P<0·05). Mortality was similar in both groups (11·6% vs. 13·7%, P=0·60). Treatment of leptospirosis with antibiotics, including the penicillin, remains controversial. The main benefit of using penicillin in the present study was a reduction in the length of hospital stay and fewer complications, such as AKI, but its use was not associated with a decrease in mortality. On balance of risks and benefits, we recommend the use of penicillin in late-stage leptospirosis.
    Journal of Clinical Pharmacy and Therapeutics 10/2011; 37(4):420-5. · 2.10 Impact Factor

Full-text (2 Sources)

Available from
Nov 25, 2013